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Abstract 
CYP2C9*3 and HLA-B alleles are reportedly associated with phenytoin-induced 
eruption in some East Asian populations; however, this finding is not readily applicable to the 
Japanese population. Thus, we aimed at investigating the risk alleles using samples and data 
from BioBank Japan. A total of 747 patients (24 cases and 723 tolerant controls) were selected 
for analysis. Case-control association studies were conducted, using CYP2C9*3, CYP2C9*27, 
CYP2C19*2, CYP2C19*3, and HLA-B allele genotype data. CYP2C9*3 carrier status was 
significantly associated with phenytoin-induced eruption (P = 0.0022, odds ratio 7.05, 95% 
confidence interval 2.44-20.4). HLA-B*51:01 showed the most prominent association (P = 
0.010, odds ratio 3.19, 95% confidence interval 1.37-7.48). Including both of these features 
improved predictive performance, measured as area under the receiver operating characteristic 
curve, by 10%. CYP2C9*3 and HLA-B*51:01 allele carrier statuses are significantly associated 
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with phenytoin-induced eruption; thus, checking this carrier status before prescription would 
decrease it in clinical practice. 
 
Introduction 
Adverse drug reactions (ADRs) remain a major concern when prescribing medications. In 
Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) reported 40,964 ADR cases in 
2012 with 2,710 associated fatalities.(1) ADR prevention is critical and identifying more risk 
factors, including genetic factors, may prevent more of the medication-associated reactions. 
Unlike disease and trait genomic researches, not much has been done in 
pharmacogenomics (PGx).(2) One of the major reasons is the difficulty of recruiting a sufficient 
number of patients with same drug response phenotypes. The Biobank Japan Project started in 
2003 and constructed a large patient-based biobank using DNA samples and clinical data relating 
to 47 target diseases with the cooperation of 12 medical institutes all over Japan.(3, 4) So far, 
many significant findings have been reported, showing the disease-gene relationships by using 
samples from BioBank Japan.(5-7) Identification of genetic variants associated with 
susceptibilities to drug toxicities is also a major objective of the BioBank Japan Project. 
Phenytoin is widely used globally, especially for epilepsy. Approximately 220,000 
phenytoin prescriptions were dispensed in Japan from 2008-2009.(8) The Phenytoin-induced 
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eruption frequency was reported to be 7%.(9) Clearly, ADR occurrences can delay timely 
therapy and lead to worse outcomes, and should be avoided. PGx studies investigating the 
associations of ADRs in phenytoin have been relatively well conducted. The Clinical 
Pharmacogenetics Implementation Consortium (CPIC) and the Royal Dutch Association for the 
Advancement of Pharmacy-Pharmacogenetics Working Group (DPWG) are well known for 
clinical support provision.(10, 11) However, these guidelines have not been utilized in clinical 
practice in Japan, given the lack of evidence on the associations with CYP2C9 and extremely low 
HLA-B*15:02 frequency in its population.(12, 13) Recently, Su et al reported the associations of 
phenytoin-induced hypersensitivity with CYP2C9*3 and HLA-B alleles in some East Asian 
populations; however, no HLA-B alleles showed significant associations in the Japanese 
population, specifically.(14) In order to achieve the targeted phenytoin dose for epilepsy 
treatment, Yamamoto et al. genotyped Japanese patients for CYP2C9*3, CYP2C19*2, and 
CYP2C19*3 and concluded that their carrier statuses are potentially useful to preventing adverse 
drug reactions; however, the sample sizes were too small and the study has not been 
replicated.(15) Considering previous PGx studies in phenytoin and allele frequencies in the 
Japanese population, the associations of phenytoin-induced eruption with CYP2C19 gene as well 
as CYP2C9 and HLA-B alleles are worth investigating. More importantly, replication of earlier 
findings would eventually lead to the clinical implementation of these genetic tests. 
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Results 
The first stage study from the BioBank Japan Project 
There was no statistically significant differences in sex or age in patients who did or did 
not develop phenytoin-induced eruption (Cases: female/male 9/15, median age 57 (range 14-81). 
Tolerant controls: female/male 278/445, median age 60 (range 8-89)). Two control samples were 
defined as undetermined in the two successive experiments; thus, were excluded from further 
analysis of HLA-B genotype data. The list of concomitant drugs of the 24 cases included in this 
study is shown in Table S1.  
The case-control association analysis for CYP2C9*3, CYP2C9*27, CYP2C19*2, and 
CYP2C19*3 showed that CYP2C9*3 carrier status is significantly associated with phenytoin-
induced eruption (P = 0.0022, odds ratio 7.05, 95% confidence interval 2.44-20.4) (Table 1). 
CYP2C9*27, CYP2C19*2 and CYP2C19*3 are not significantly associated with the risk of 
developing the eruption (Table S2).  
 Additionally, HLA-B allele associations were comprehensively assessed and the most 
prominent was the association of HLA-B*51:01 (P = 0.010, odds ratio 3.19, 95% confidence 
interval 1.37-7.48) (Table 2), which did not show significant association in the previous report 
due to the small sample size.(14) The association with HLA-B*13:01 was not statistically 
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significant (P = 0.10). No one in the cases and tolerant controls possessed the HLA-B*15:02 
allele. One case and three tolerant controls had both of the risk factors of CYP2C9*3 and HLA-
B*51:01. The coefficient of epistatic effect was -0.4212 (95% CI: 0.0272- 7.37), and not 
significant (P=0.74) after conditioning on the main effects. When included in multiple logistic 
regression analysis, both factors were significantly associated with the eruption as independent 
predictors (Table 3). 
 From the receiver-operating characteristic (ROC) curve for prediction of the risk of non-
SCAR eruption, the area under curve (AUC) from a combination of CYP2C9*3 and HLA-
B*51:01 carrier information was significantly improved by 10%, compared with only the 
CYP2C9*3 carrier status (P = 0.028) (Figure 1). The diagnostic performance of the predictive 
model is shown in Table 4. 
 
Confirmation study 
 There were no statistically significant differences in sex or age in patients who did or 
did not develop eruption, combining samples from both of BioBank Japan and the Japanese 
Research Committee on Severe Cutaneous Adverse Reaction (JSCAR)(16) (Cases: female/male 
14/19, median age 57 (range 14-81). Tolerant controls: female/male 278/445, median age 60 
(range 8-89)). The list of possible causative drugs of the cases from JSCAR is shown in Table 
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S3. Phenytoin is the only drug that all cases were on. The frequencies of the cases with 
CYP2C9*3, CYP2C9*27, CYP2C19*2, CYP2C19*3, HLA-B*51:01, and HLA-B*13:01 alleles in 
the confirmation study were 11.1%, 33.3%, 22.2%, 55.6%, 33.3%, and 22.2%, respectively. The 
case-control association analysis for CYP2C9*3, CYP2C9*27, CYP2C19*2, and CYP2C19*3 
showed the same signals as the original study (Table 5). Comprehensive assessment of HLA-B 
allele associations showed that HLA-B*13:01 and HLA-B*51:01 revealed the prominent findings 
(P = 0.0074, odds ratio 6.49, 95% confidence interval 2.02-20.8 for HLA-B*13:01. P = 0.0064, 
odds ratio 3.04, 95% confidence interval 1.46-6.36 for HLA-B*51:01) (Table 5). Table 5 
describes the association analyses for three categories of patients: 1. Overall cohort (33 cases), 2. 
Cases with SCAR, 3. Cases without SCAR. A summary of 33 cases describing their clinical 
phenotypes, CYP2C9*3 and HLA-B*51:01 status is shown in Table S4.  
 Finally, a meta-analysis of the association of risk for developing phenytoin-induced 
eruption was conducted from the previous studies (Figure 2).(12, 14) CYP2C9*3 carrier status 
was significantly associated with the eruption both in Japanese and other East Asians. 
Additionally, HLA-B*51:01 is also associated with the risk of developing the eruption in 
Japanese as well as other East Asians, which is a novel and significant finding in the Japanese 
population as it showed positive relationships in all of the East Asian populations included. 
 
9 
 
Discussion 
This study successfully identified the HLA-B risk allele and validated the association of 
phenytoin-induced eruption with CYP2C9*3 in the Japanese population. This is the first study 
demonstrating the HLA-B*51:01 allele’s association and successfully replicating the CYP2C9*3 
association study with phenytoin-induced eruption in Japanese. 
As per the FDA drug labeling, the most frequently seen phenytoin-related adverse reaction 
to the central nervous system includes nystagmus, ataxia, dizziness, and headaches.(17) 
Dermatological findings are also possible major side effects, with the most common being 
morbilliform rash, and most serious being Stevens–Johnson syndrome/toxic epidermal necrolysis 
(SJS/TEN).(17) The frequency of phenytoin-induced eruptions was reported to be 7%.(9) Also, a 
case-control study reported that among 73 patients with SJS/TEN, 14 patients were on phenytoin, 
indicating that phenytoin-mediated SJS/TEN is common.(18) Given the high mortality rate of 
severe cutaneous reactions, apparent patient discomforts, and potential for delaying optimal 
treatments regardless of the phenotypes of dermatological findings, it is critical to maximize efforts 
to prevent these side effects, which was the main aim for the present study.(9, 19, 20) 
Phenytoin is primarily metabolized to the inactive 4-hydroxyphenytoin by CYP2C9, then 
to glucuronidated, and then excreted into urine.(21, 22) Patients with CYP2C9*2 and CYP2C9*3 
alleles have decreased hepatic CYP2C9 activity, indicating that patients receiving phenytoin are 
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prone to developing adverse reactions due to their reduced ability to inactivate phenytoin.(23, 24) 
Heterozygotes for CYP2C9 genotype, *1/*3 or *1/*2, are defined as CYP2C9 intermediate 
metabolizers, and homozygotes for variant alleles, *2/*2, *2/*3, or *3/*3, as CYP2C9 poor 
metabolizers, considered to be more prone to developing adverse reactions. In addition, several 
studies have shown associations between HLA-B and phenytoin-induced eruption. The HLA allele 
mechanisms involved in eruption development remain unclear, but several hypotheses have been 
suggested. First is the hapten/prohapten hypothesis, where a chemically active drug or metabolite 
covalently binds to an endogenous peptide that is subsequently presented by a particular HLA. 
Secondly, the pharmacological interaction of drugs with immune receptors (the p-i concept); a 
direct/reversible interaction of drugs with T-cell receptors or peptide-loaded HLAs, triggers 
immune reactions. Thirdly, the direct interaction between HLA/peptide and an immune reaction-
initiating drug in patients carrying specific HLA allele(s).(25-27) Given the current researches and 
theories surrounding this phenomenon, it is essential to identify these two alleles in predicting 
phenytoin-induced adverse reactions.  
The CPIC guideline does not recommend phenytoin/fosphenytoin for HLA-B*15:02 
carriers, regardless of their CYP2C9 genotype, but alternatives not affected by this CYP2C9 
phenotype.(11) Dose adjustment is recommended for HLA-B*15:02 non-carriers, based on the 
CYP2C9 genotype (50% reduction of usual starting maintenance dose for CYP2C9 poor 
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metabolizers; and 25% reduction for intermediate metabolizers), to prevent adverse reactions. The 
CPIC guideline recommends close therapeutic drug monitoring for dose adjustment in pediatric 
patients, as their hepatic CYP2C9 activity levels are only optimum around 5 months to 2 years of 
age.(28, 29) The DPWG guidelines corroborate these recommendations.(10) However, the 1000 
Genomes Project did not observe CYP2C9*2 in the Japanese population.(30) Therefore, 
CYP2C9*3 carrier status would be sufficient to decrease the probability of adverse reactions 
associated with phenytoin in the Japanese population. The HLA-B*15:02 frequency in the Japanese 
population was reported to be 0.0002 - 0.001; thus, the clinical utility of the allele in Japanese is 
quite low.(13, 31, 32) Conversely, the HLA-B*51:01 allele frequencies in Japanese was reported 
to be 0.077 - 0.083.(13, 31, 32) Considering all of these facts and our findings, CYP2C9*3 and 
HLA-B*51:01 would significantly decrease phenytoin-related adverse reactions and affect clinical 
outcomes in Japanese patients. 
The results of our diagnostic performance showed high specificity and NPV, meaning that 
these alleles can better predict which patients can be safely administered these drugs (Table 5). 
Furthermore, the number needed to screen (NNS) (26) in this study was lower than those calculated 
in our previous studies which reported HLA-A*31:01 allele as a risk factor for carbamazepine-
induced cutaneous ADRs in the Japanese population, with NNS of 33 (calculated using the 
carbamazepine-induced cutaneous ADRs incidence of 5.1%).(33, 34) Thus, our results strongly 
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suggest that these alleles may be used for screening in clinical practice. The occurrence of all of 
the aforementioned pathological skin findings delay timely therapies and lead to worse outcomes. 
Therefore, target patient identification is very important in phenytoin prescription in actual clinical 
situations; hence, high negative predictive value is critical in assessing the clinical utility of these 
tests, supporting the significance of our findings. Furthermore, the number needed to test is also 
as low as 26, meaning that significant number of patients could be identified for safer phenytoin 
therapies, which also supports the usefulness of these tests. 
This is the first study to have identified the associations of the HLA-B allele with phenytoin-
induced eruption in the Japanese population. The meta-analysis of our results and previous studies 
showed no heterogeneities (Figure 2). Additionally, the AUC of the ROC curve for the prediction 
of risk of eruption became nearly 70% with the CYP2C9*3 and HLA-B*51:01 combination. 
Currently, there are no tests to predict eruption development when prescribing phenytoin; hence, 
checking carrier status of these alleles is crucial in providing better outcomes. 
In our study, an association analysis of CYP2C19*2 and CYP2C19*3 with phenytoin-
induced eruption was conducted, which resulted in negative findings. Though there is an 
annotation on the FDA label for phenytoin and CYP2C19 allele variants regarding the risk of high 
phenytoin concentration, CYP2C19 metabolizes phenytoin only when the pathway is saturated 
with high phenytoin concentrations; thus, carrier status of CYP2C19 alleles would usually not 
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cause major problems in clinical practice.(17, 35) Also, this study reported no patients with the 
CYP2C9*3 allele among the CYP2C19 poor metabolizers with two loss-of-function alleles (*2/*2, 
*2/*3, *3/*3) resulting in reduced or no CYP2C19 activity. Thus, we could not make further 
inferences about CYP2C19*2 and CYP2C19*3 involvement in the patients who developed 
phenytoin-induced eruption with CYP2C9*3. Till now, no strong evidence exists relating to the 
associations of phenytoin-related adverse reactions with CYP2C19*2 and CYP2C19*3,(12, 36) 
and our results corroborate these findings. 
In our study, we have successfully confirmed the association of two risk alleles in 
additional samples from JSCAR. Additionally, the results showed that the phenotype is 
prominently associated with the HLA-B*13:01. Previously, this association was reported by Su et 
al. for non-Japanese population; however this result is novel for the Japanese population.(14) In 
light of this, we acknowledge that there is still a need for further study in the Japanese population 
before this result can inform potential improvements in clinical practice. 
The incidence of phenytoin induced eruptions estimated in our retrospective study from 
the BioBank Japan Project was 3.2%, and the incidence was lower than previously reported 
(7%).(9) Currently, no studies regarding the incidence of phenytoin-induced eruption in the 
Japanese population have been conducted, and thus we have used the data reported by UK research 
group in order to show the diagnostic performance of the predictive model we developed. Thus, in 
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the present study, one of the reasons for the lower incidence of eruption by phenytoin could be the 
genetic diversity between different populations, indicating that there may be genetic factors 
involved in the susceptibility to the phenytoin-induced eruption. 
 Lastly, we conducted a meta-analysis by combining the study by Su et al.(8) All of the 
Japanese patients included in the study by Su et al. had severe cutaneous adverse reactions 
(SCAR), and our cases from the BioBank Japan Project had non-SCAR, including mild rashes. 
The stratification analyses of patients with SCAR only was not statistically significant, as shown 
in Table 5. However, this result may be explained by the very small number of patients, which 
was only six in this case. Thus, our findings could definitely add new important insights in 
addition to those previously reported by Su et al.; specifically that the risk factors could be used 
not only to predict SCAR, but also mild rashes when prescribing phenytoin. 
This study was limited by the number of cases (24) included from the BioBank Japan 
Project; however, we were able to successfully replicate the known association of CYP2C9*3 
and identified the statistical significance of HLA-B*51:01 allele association in the Japanese 
population, which was verified by adding nine more cases from JSCAR. Additionally, the meta-
analysis of the results of this study and previous reports maintained the positive association, 
suggesting strong support for our findings.(14) Secondly, our findings better predicted the 
development of phenytoin-induced eruption, but did not completely explain the reasons for the 
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development, given the fact that the AUC of the ROC curve was improved to nearly as high as 
70% with the CYP2C9*3 and HLA-B*51:01combination. Other factors should be considered in 
future studies; however, we have added a meaningful risk component, which could definitely 
prevent phenytoin-related adverse reactions in a number of patients. 
In conclusion, two risk alleles for developing phenytoin-induced eruption; CYP2C9*3 and 
HLA-B*51:01, were identified in the Japanese population. Their statuses should be checked before 
phenytoin prescription to Japanese patients in clinical practice to prevent adverse reactions, 
provide timely therapy, and improve outcomes. 
 
Methods 
The first stage study from the BioBank Japan Project  
Subjects 
 The study’s protocol was approved by the ethical committees from the Institute of 
Medical Sciences, University of Tokyo (Tokyo, Japan) and the RIKEN Center for Integrative 
Medical Sciences (Yokohama, Japan) and patients recruited for the BioBank Japan Project 
provided written informed consent. The medical coordinator collected the data regarding any 
ADRs from the medical records created by the medical doctors working in the BioBank Japan 
affiliated hospitals between April 2003 and March 2018, and this data has been stored in the 
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database of BioBank Japan Project. In this study, we retrieved the data for patients who 
developed or did not develop eruption while on phenytoin. A total of 747 patients were 
retrospectively selected for the analyses (24 cases and 723 tolerant controls). All 24 patients had 
a non-SCAR phenytoin-induced eruption, in particular one had erythema multiforme, four had 
erythema, one had erythroderma, one had fixed drug eruption, two had maculopapular 
exanthema and fifteen had unspecified mild eruption.  
 
Genotyping of SNPs of CYP2C9 and CYP2C19 
The DNA of the cases and controls were genotyped for CYP2C9*3, CYP2C9*27, 
CYP2C19*2, and CYP2C19*3; rs1057910 (1075A>C), rs12782374 (-3089G>A), rs4244285 
(681G>A), and rs4986893 (636G>A) respectively, using multiplex PCR followed by an Invader 
assay, as previously described by Ohnishi, et al.(37) In addition to CYP2C9*3, CYP2C19*2, and 
CYP2C19*3, we decided to genotype CYP2C9*27, considering the study by Chaudhry et al. 
which showed the association of change in clearance/metabolism of phenytoin with the allele, 
and also the frequency of the allele in Japanese population is high enough and thus worth 
investigating.(38) Briefly, 10 ng of genomic DNA was amplified in a total reaction volume of 20 
μl using Ex Taq HS DNA polymerase (5 U/μl) (Takara Bio, Otsu, Japan). All PCRs were 
performed with an initial denaturation at 95°C for 5 min, followed by 40 denaturation cycles at 
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95°C for 15 s, annealing at 58°C for 45 s, extension at 72°C for 2 min, and a final extension at 
72°C for 5 min, except for CYP2C9*27 for which the annealing temperature was set at 50°C, 
using a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA). Then, the 
products were diluted 10-fold and used as templates for the Invader assay, using ABI PRISM 
7900 (Applied Biosystems), as recommended by Hologic (Marlborough, MA, USA). 
 
Genotyping of HLA-B alleles 
HLA-B four-digit allele genotyping was performed on a Luminex 200 system, using a 
WAKFlow HLA Typing kit, following the manufacturer's instructions (Wakunaga 
Pharmaceutical, Hiroshima, Japan). Hybridization patterns were classified, using the software 
provided by the manufacturer, WAKFlow Manager. HLA alleles were selectively genotyped 
because previous reports showed significant associations of HLA-B alleles with phenytoin-
induced eruption in some East Asian populations.(14, 36) 
 
Data and Statistical Analyses 
Association studies were conducted using Fisher’s exact test for categorical variables, 
and Mann-Whitney's U test for continuous variables, and associations with P <0.05 were 
considered statistically significant. In the association analysis of HLA-B alleles with phenytoin-
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induced eruption, odds ratios and 95% confidence intervals were calculated for the HLA-B alleles 
with P < 0.05 only. Subsequently, multivariate logistic regression analysis with stepwise variable 
selection was conducted to identify independent factors associated with phenytoin-induced 
eruption. Additionally, the diagnostic performance of the predictive model using CYP2C9*3 and 
HLA-B*51:01 carrier statuses between cases and controls were evaluated. Sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), and number needed to screen 
(NNS) were calculated. Finally, a receiver-operating characteristic (ROC) curve was plotted with 
true positive (sensitivity) versus false positive rates (1-specificity), and the area under curve 
(AUC) used to evaluate how well the prediction model distinguishes the risks of phenytoin-
induced eruption. The ROC curves of the prediction models were compared using DeLong’s 
test.(40, 41) All the analyses were carried out using R statistical environment (version 3.5.0).(42) 
The data and statistical analyses comply with the recommendations on experimental design and 
analysis in pharmacology.(43)  
 
Confirmation of the first stage study in the BioBank Japan Project 
In order to confirm our findings from the first stage, we conducted a confirmation study 
by adding additional nine cases to our original study. Nine unrelated Japanese patients were 
enrolled in this study, who presented with eruption induced by phenytoin at institutes belonging 
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to JSCAR from October 2005 to February 2015. The diagnoses of SJS/TEN and drug-induced 
hypersensitivity syndrome (DIHS) were performed according to the appropriate clinical 
criteria.(44, 45) Final diagnoses were assigned as follows: DIHS, 5 patients; TEN, 1 patient; 
erythema multiforme, 1 patient; others, 2 patients. Genotyping of CYP2C9, CYP2C19, and HLA-
B, and statistical analyses were conducted as stated above. 
Additionally, meta-analysis was conducted using RevMan version 5.3.5 (Cochrane 
Collaboration, Oxford, UK).(39) 
 
Study Highlights 
What is the current knowledge on the topic? 
• CYP2C9*3 and HLA-B alleles are significantly associated with phenytoin-induced 
hypersensitivity in some East Asian populations. 
• However, the data is not necessarily applicable to the Japanese population.  
• Thus, currently, no strong evidence exists showing phenytoin-induced eruption 
associations in the Japanese population. 
What question did this study address? 
• We sought to investigate the associations of phenytoin-induced eruption with CYP2C19 
gene as well as CYP2C9 and HLA-B alleles. 
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What does this study add to our knowledge?  
• CYP2C9*3 and HLA-B*51:01 alleles were significantly associated with phenytoin-
induced eruption in the Japanese population. 
• HLA-B*51:01 and CYP2C9*3 allele combination improved the prediction model. 
How might this change clinical pharmacology or translational science? 
• In the Japanese population, CYP2C9*3 and HLA-B*51:01 allele carrier statuses could 
be used during prescription in clinical practice.  
• It could decrease phenytoin-induced eruption and provide the best possible treatment for 
patients. 
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Figure legends 
Figure 1. Receiver-operating characteristic (ROC) curve for predicting the risk of phenytoin-
induced eruption 
The black line shows the ROC curve for the model that used CYP2C9*3 genotyping data only. 
The blue line shows the ROC curve for the HLA-B*51:01-based model. The red line shows the 
ROC curve for the HLA-B*51:01 and CYP2C9*3 genotyping data combination model. The area 
under the curve (AUC) values of the black, blue, and red lines were 0.586 (95% confidence 
interval 0.503-0.670), 0.608 (95% confidence interval 0.509-0.708), and 0.686 (95% confidence 
interval 0.579-0.794), respectively, showing a 10% improved predictive performance compared 
to the CYP2C9*3-only model (P = 0.028 by DeLong’s test). 
 
Figure 2. Meta-analysis of CYP2C9*3 or HLA-B*51:01 association with the risk of developing 
phenytoin-induced eruption in Japanese and other East Asians 
A: CYP2C9*3 association with the risk of the eruption in the Japanese population. CYP2C9*3 
carrier status is significantly associated with the eruption. 
B: CYP2C9*3 association with the risk of the eruption in East Asians. CYP2C9*3 carrier status 
is significantly associated with the eruption in all four populations included. 
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C: HLA-B*51:01 association with the risk of the eruption in the Japanese population. After the 
meta-analysis, the HLA-B*51:01 allele showed a statistically significant association with the 
eruption, from negative with only the data from the Japanese patients in the study by Su et al. to 
positive by addition of data from our study (12, 14). 
D: HLA-B*51:01 association with the risk of the eruption in East Asians. The HLA-B*51:01 
allele is significantly associated with the eruption in all three populations included. 
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Table 1. Association between CYP2C9*3 and phenytoin-induced eruption in the first stage study from the BioBank Japan Project 
 
 CYP2C9*3  
carriers 
CYP2C9*3  
non-carriers 
 
Case  
(n = 24) 
5 (20.8%) 19 (79.2%)  
Control  
(n = 723) 
26 (3.6%) 697 (96.4%) 
P = 0.0022  
Odds ratio:7.05 (95% CI: 2.44-20.4) 
 
CI, confidence interval 
  
 1 
 
Table 2. Associations of HLA-B alleles with phenytoin-induced eruption in the first stage study from the BioBank Japan Project 
 
 
Case (n = 24) Control (n = 721) 
p value 
Odds ratio 
(95% CI) Carrier (%) Non-carrier (%) Carrier (%) Non-carrier (%) 
B*07:02 2 (8.3) 22 (91.7) 71 (9.8) 650 (90.2) 1.0  
B*07:05 0 (0.0) 24 (100) 1 (0.1) 720 (99.9) 1.0  
B*13:01 2 (8.3) 22 (91.7) 15 (2.1) 706 (97.9) 0.10  
B*13:02 0 (0.0) 24 (100) 4 (0.6) 717 (99.4) 1.0  
B*15:01 1 (4.2) 23 (95.8) 117 (16.3) 604 (83.8) 0.15  
B*15:07 0 (0.0) 24 (100) 6 (0.8) 715 (99.2) 1.0  
B*15:11 0 (0.0) 24 (100) 13 (1.8) 708 (98.2) 1.0  
B*15:18 2 (8.3) 22 (91.7) 16 (2.2) 705 (97.8) 0.11  
B*27:04 0 (0.0) 24 (100) 7 (1.0) 714 (99.0) 1.0  
B*35:01 5 (20.8) 19 (79.2) 146 (20.3) 575 (79.8) 1.0  
B*37:01 0 (0.0) 24 (100) 11 (1.5) 710 (98.5) 1.0  
B*38:02 1 (4.2) 23 (95.8) 3 (0.4) 718 (99.6) 0.12  
B*39:01 0 (0.0) 24 (100) 56 (7.8) 665 (92.2) 0.25  
B*39:02 0 (0.0) 24 (100) 5 (0.7) 716 (99.3) 1.0  
B*39:04 1 (4.2) 23 (95.8) 2 (0.3) 719 (99.7) 0.094  
B*39:23 0 (0.0) 24 (100) 1 (0.1) 720 (99.9) 1.0  
B*40:01 3 (12.5) 21 (87.5) 84 (11.6) 637 (88.3) 0.75  
B*40:02 2 (8.3) 22 (91.7) 105 (14.6) 616 (85.4) 0.56  
B*40:03 0 (0.0) 24 (100) 8 (1.1) 713 (98.9) 1.0  
B*40:06 3 (12.5) 21 (87.5) 52 (7.2) 669 (92.8) 0.41  
B*44:02 0 (0.0) 24 (100) 5 (0.7) 716 (99.3) 1.0  
 2 
 
B*44:03 4 (16.7) 20 (83.3) 96 (13.3) 625 (86.7) 0.55  
B*46:01 2 (8.3) 22 (91.7) 57 (7.9) 664 (92.1) 1.0  
B*48:01 1 (4.2) 23 (95.8) 51 (7.1) 670 (92.9) 1.0  
B*51:01 9 (37.5) 15 (62.5) 114 (15.8) 607 (84.2) 0.01 
3.19 
(1.37-7.48) 
B*51:02 0 (0.0) 24 (100) 4 (0.6) 717 (99.4) 1.0  
B*52:01 2 (8.3) 22 (91.7) 125 (17.3) 596 (82.7) 0.41  
B*54:01 2 (8.3) 22 (91.7) 102 (14.1) 619 (85.9) 0.56  
B*55:02 0 (0.0) 24 (100) 35 (4.9) 686 (95.1) 0.62  
B*55:04 1 (4.2) 23 (95.8) 2 (0.3) 719 (99.7) 0.094  
B*56:01 0 (0.0) 24 (100) 17 (2.4) 704 (97.6) 1.0  
B*56:03 1 (4.2) 23 (95.8) 2 (0.3) 719 (99.7) 0.094  
B*58:01 0 (0.0) 24 (100) 7 (1.0) 714 (99.0) 1.0  
B*59:01 2 (8.3) 22 (91.7) 30 (4.1) 691 (95.8) 0.28  
B*67:01 1 (4.2) 23 (95.8) 12 (1.7) 709 (98.3) 0.35  
 
CI, confidence interval  
 1 
 
Table 3. Multiple logistic regression analysis for variables independently and significantly 
associated with phenytoin-induced eruption 
 
Variable Coefficient SE p value Odds ratio 95% CI 
(Intercept) -3.936 0.2908 <2.0e-16   
CYP2C9*3 2.064 0.5550 0.00020 7.88 2.66-23.4 
HLA-B*51:01 1.251 0.4449 0.0049 3.49 1.46-8.35 
 
SE, standard error; CI, confidence interval 
 
 
 
 
 
 
 
 
 
 
 
  
 1 
 
Table 4. Diagnostic performance of the concurrent use of two risk factors associated with non-
SCAR phenytoin-induced eruption, CYP2C9*3, and HLA-B*51:01  
 
 Positive Negative 
Case n (%) 13 (54.1) 11 (45.8) 
Control n (%) 137 (19.0) 584 (81.0) 
Sensitivity (%) 54.2 
Specificity (%) 81.0 
Positive predictive value (%) 17.7 
Negative predictive value (%) 95.9 
Number needed to screen 26.3 
Positive: patients with CYP2C9*3 or HLA-B*51:01; negative: patients without CYP2C9*3 or 
HLA-B*51:01; frequency of phenytoin-induced eruption: 7%, reported by Chadwick et al. [9]  
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Table 5. Associations of CYP2C9*3, CYP2C9*27, CYP2C19*2 CYP2C19*3 and HLA-B alleles 
with phenytoin-induced eruption in a confirmation study 
CI, confidence interval; SCAR, severe cutaneous adverse reactions 
 Carrier (%) Non-carrier (%) p value Odds ratio (95% CI) 
CYP2C9*3     
All cases (n = 33) 6 (18.2) 27 (81.8) 0.0017 5.96 (2.26-15.7) 
SCAR cases (n = 6) 1 (16.7) 5 (83.3) 0.20 5.36 (0.605-47.5) 
Non-SCAR cases (n = 27) 5 (12.5) 22 (55.0) 0.0037 6.09 (2.14-17.4) 
Control (n = 723) 26 (3.6) 697 (96.4)   
CYP2C9*27     
All cases (n = 33) 13 (39.4) 20 (60.6) 0.15 0.574 (0.281-1.17) 
SCAR cases (n = 6) 2 (33.3) 4 (66.7) 0.43 0.441 (0.0803-2.43) 
Non-SCAR cases (n = 27) 11 (40.7) 16 (59.3) 0.24 0.607 (0.278-1.33) 
Control (n = 723) 384 (53.1) 339 (46.9)   
CYP2C19*2     
All cases (n = 33) 12 (36.4) 21 (63.6) 0.22 0.623 (0.302-1.28) 
SCAR cases (n = 6) 1 (16.7) 5 (83.3) 0.22 0.218 (0.0253-1.87) 
Non-SCAR cases (n = 27) 11 (40.7) 16 (59.3) 0.56 0.749 (0.343-1.64) 
Control (n = 723) 346 (48.9) 377 (52.1)   
CYP2C19*3     
All cases (n = 33) 8 (24.2) 25 (75.8) 0.67 1.15 (0.510-2.61) 
SCAR cases (n = 6) 3 (50.0) 3 (50.0) 0.12 3.61 (0.721-18.0) 
Non-SCAR cases (n = 27) 5 (18.5) 22 (81.5) 0.82 0.819 (0.305-2.20) 
Control (n = 723) 157 (21.7) 566 (78.3)   
HLA-B*13:01     
All cases (n = 33) 4 (12.1) 29 (87.9) 0.0074 6.49 (2.02-20.8) 
SCAR cases (n = 6) 2 (33.3) 4 (66.7) 0.0073 23.5 (4.00-139) 
Non-SCAR cases (n = 27) 2 (7.4) 25 (92.6) 0.12 3.77 (0.817-17.4) 
Control (n = 721) 15 (2.1) 706 (97.9)   
HLA-B*51:01     
All cases (n = 33) 12 (36.4) 21 (63.6) 0.0064 3.04 (1.46-6.36) 
SCAR cases (n = 6) 2 (33.3) 4 (66.7) 0.25 2.67 (0.482-14.7) 
Non-SCAR cases (n = 27) 10 (37.0) 17 (63.0) 0.0074 3.13 (1.40-7.01) 
Control (n = 721) 114 (15.8) 607 (84.2)   
 1 
 
Figure 1 
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Figure 2 
A: CYP2C9*3 (Japanese) 
 
B: CYP2C9*3 (East Asians) 
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C: HLA-B*51:01 (Japanese) 
 
D: HLA-B*51:01 (East Asians) 
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Table S1. Concomitant drugs of the 24 cases included in the first stage study from the BioBank 
Japan Project 
 
Patient Concomitant drugs 
1 Loxoprofen, ranitidine 
2 Valproate, amoxicillin, cilostazol, lansoprazole 
3 None 
4 Valproate, carbamazepine 
5 Carbamazepine 
6 Cefditoren, tizanidine 
7 Valproate, carbamazepine 
8 Valproate 
9 None 
10 Phenobarbital, zonisamide, valproate, clobazam, atorvastatin 
11 None 
12 Valproate 
13 Carbamazepine 
14 Zonisamide, indometacin, tizanidine, pravastatin 
15 None 
16 Phenobarbital, zonisamide, atorvastatin, aspirin, fexofenadine, ranitidine 
17 None 
18 Diltiazem 
19 None 
20 None 
21 None 
22 None 
23 None 
24 None 
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Table S2. Associations of CYP2C19*2, CYP2C19*3 and CYP2C9*27 with phenytoin-induced eruption in the first stage study from 
the BioBank Japan Project 
 
 
Case (n = 24), 
genotype 
Control (n = 723), 
genotype 
Case,  
frequency (%) 
Control,  
frequency (%) 
p value  
 AA AG GG AA AG GG AA AG GG AA AG GG A vs G 
AA vs 
AG+GG 
AA+AG 
vs GG 
CYP2C19*2 
(rs4244285) 
2 8 14 67 279 377 8.3 33.3 58.3 9.3 38.6 52.1 0.75 1.0 0.68 
CYP2C19*3 
(rs4986893) 
0 3 21 8 149 566 0.0 12.5 87.5 1.1 20.6 78.3 0.36 1.0 0.45 
CYP2C9*27 
(rs12782374) 
2 8 14 79 305 339 8.3 33.3 58.3 10.9 42.2 46.9 0.35 1.0 0.30 
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Table S3. Possible causative drugs of the nine cases from the Japanese Research Committee on 
Severe Cutaneous Adverse Reaction 
 
Patient Drugs 
1 Phenytoin 
2 Phenytoin 
3 Phenytoin 
4 Phenytoin 
5 Phenytoin 
6 Carbamazepine, phenobarbital, phenytoin 
7 Phenytoin 
8 Phenytoin 
9 Levetiracetam, phenytoin 
 
 1 
 
Table S4. Summary of 33 cases describing their clinical phenotypes, CYP2C9*3, HLA-B*13:01 and HLA-B*51:01 status 
 
Phenotype Cases 
CYP2C9*3 
carriers 
HLA-B*13:01 
carriers 
HLA-B*51:01 
carriers 
Drug-induced hypersensitivity syndrome 5 0 2 1 
Toxic epidermal necrolysis 1 1 0 1 
Erythema multiforme 2 0 0 1 
Erythroderma 1 0 1 0 
Fixed drug eruption 1 0 0 0 
Maculopapular exanthema 2 1 1 1 
Erythema 3 0 0 0 
Unspecified mild eruption 18 4 0 8 
Total 33 6 4 12 
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